The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

4 months ago

Version History

4 additional sources confirmed this story

Version 14 months ago

What changed: Updated to include the approval of Anktiva in China, marking the company's first entry into the Asian market and expansion to 34 global markets.

StocksHigh ImpactUpdated•Originally published 24 March 2026•Updated 24 March 2026•

1 min read

ImmunityBio Shares Recover After China Approves Anktiva Cancer Therapy

Key Facts

1ImmunityBio shares fell 20% on Tuesday following a warning letter from the U.S. Food and Drug Administration.

2The FDA stated that a television advertisement and podcast promoting the company's cancer therapy contained false or misleading claims.

3The promotional materials in question violated federal law regarding the promotion of medical therapies.

ImmunityBio Inc. (IBRX) received a major boost as China approved its Anktiva combination therapy for the treatment of bladder cancer. This milestone marks the company's first regulatory approval in the Asian market, significantly broadening its international footprint. With this latest authorization, ImmunityBio's global reach has expanded to 34 markets worldwide. The positive news comes shortly after the company faced a 20% stock decline following an FDA warning regarding misleading promotional materials in the U.S. Investors are now weighing the potential of the Chinese market against the recent regulatory challenges faced domestically. The expansion into China represents a critical step in the company's strategy to commercialize its flagship oncology treatments globally.

Sources:

reuters.com

benzinga.com

investing.com